Equity Overview
Price & Market Data
Price: $2.64
Daily Change: -$0.08 / 3.03%
Daily Range: $2.55 - $2.77
Market Cap: $155,673,696
Daily Volume: 221,470
Performance Metrics
1 Week: 7.53%
1 Month: 41.99%
3 Months: 54.82%
6 Months: 82.27%
1 Year: 86.23%
YTD: 21.80%
Company Details
Employees: 61
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.